Drug Trial Radar · NCT06349759
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Apr 1, 2024
Primary completion
Apr 17, 2025
Study completion Feb 19, 2026
Sponsor
- Lead sponsor
- Opus Genetics, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Viatris Inc.
- First posted
- Apr 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances.
Conditions
- Mesopic Vision
- Night Vision Loss
Interventions
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonistDrug
Once daily dosing
PlaceboDrug
Once daily dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With ≥ 15 Letters (3 Lines) Improvement in mLCVA in the Study Eye at Day 15 Compared to BaselineTime frame: 15 Days
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
United States Phoenix
Pheonix, Arizona
United States Scottsdale
Scottsdale, Arizona
United States
Bakersfield, California
United States, Glendale, CA
Glendale, California
United States, LaJolla, CA
La Jolla, California
United States, California
Newport Beach, California
United States Rowland Heights
Rowland Heights, California
United States Torrance
Torrance, California
United States, Jacksonville, FL
Jacksonville, Florida
United States Jacksonville
Jacksonville, Florida
United States
Tampa, Florida
United States Overland Park
Overland Park, Kansas
United States Louisville
Louisville, Kentucky
United States Fraser
Fraser, Michigan
United States
New York, New York
United States Smithtown
Smithtown, New York
United States, North Carolina
Garner, North Carolina
United States Fargo
Fargo, North Dakota
United States
Fargo, North Dakota
United States, Rhode Island
Warwick, Rhode Island
United States, Mt Pleasant, SC
Mt. Pleasant, South Carolina
United States Chattanooga
Chattanooga, Tennessee
United States Smyrna
Smyrna, Tennessee
United States Draper
Draper, Utah
United States Lynchburg
Lynchburg, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.